Alderley Analytical
Alderley Analytical is recorded as a service provider in 13 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 13 of 13 trials · Latest update first
A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma
Sponsor Renaissance Pharma Limited
- Start (EU)
- Latest update
- Estimated end
A Randomised, Placebo-Controlled, 3-Arm, Double-Blind, Multicentre, Phase 4 Study to Assess the Efficacy of OM-85 (Broncho Vaxom) Short- and Long-Term Treatment vs. Placebo in the Prevention of Respiratory Tract Infections in Children Aged Between 6 Months and 5 Years with Wheezing Lower Respiratory Illness
Sponsor OM Pharma SA
- Start (EU)
- Latest update
- Estimated end
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in combination with Nivolumab and Lenvatinib compared to Double Placebo and Lenvatinib in Participants with Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) after Failure of First-Line Treatment that Included an Anti-PD-(L)1 Compound (GDFATHER-HCC-01)
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
CT7001_002 (SUMIT-BC) - An open-label Interventional, Multicenter, Randomized, Phase 2 Study of Fulvestrant with or without Samuraciclib in Participants with Metastatic or Locally Advanced Hormone Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Sponsor Carrick Therapeutics Limited
- Start (EU)
- Latest update
- Estimated end
A Randomized Double-Blind Study to Evaluate the Efficacy and Safety of CAL101 in Patients with Idiopathic Pulmonary Fibrosis
Sponsor Calluna Pharma AS
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab plus Nivolumab with or without Docetaxel versus Docetaxel Monotherapy in Second-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-02)
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab versus Placebo, in Combination with Pembrolizumab, Pemetrexed, and Carboplatin, in First-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-01)
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in combination with an anti-PD-1 checkpoint inhibitor in subjects with advanced-stage, relapsed/refractory solid tumors.
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced haematological malignancies
Sponsor Cellcentric Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Open-Label Study of Samuraciclib in Combination with Elacestrant in Participants with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Sponsor Carrick Therapeutics Limited
- Start (EU)
- Latest update
- Estimated end
Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.
Sponsor Bergenbio ASA
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Alderley Analytical?
The 2026-10-09 snapshot links Alderley Analytical to 13 distinct CTIS trials. Recorded services include Laboratory services, additional PK analysis, PK (Samuraciclib), PK Analysis. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Alderley Analytical?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Respiratory, Gastroenterology, Hepatology. Recorded phases include Phase 2, Phase 3, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Alderley Analytical conducted?
The linked trials record locations in 14 countries, including Spain, Italy, Germany, France, Poland. These are trial locations, not confirmed office locations or countries where Alderley Analytical delivered services.
What can this page tell me about Alderley Analytical's trial experience?
Browse 13 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Alderley Analytical. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Alderley Analytical Limited